Cancers & treatments·Regimen libraryFirst line

Pembrolizumab + carboplatin + paclitaxel

Checked 2026-09-09

Metastatic squamous NSCLC, first line

One cycle

every 21 days × 4 · about 12 weeks in total

21-day cycle × 4 with chemotherapy, then pembrolizumab up to 35 (about 12 weeks)Intravenous

Components

Drug	Dose	Route	Days	Note
Pembrolizumab Monoclonal antibody (anti-PD-1)	200 mg	IV	D1	or 400 mg every 6 weeks
Carboplatin Cytotoxic chemotherapy (platinum)	AUC 6	IV	D1
Paclitaxel 200 mg/m² day 1, or nab-paclitaxel 100 mg/m² days 1, 8, 15 Cytotoxic chemotherapy (taxane)	cycles 1-4	IV	D1

Cycles

4 with chemotherapy, then pembrolizumab up to 35

21-day cycle

Emetogenicity

Moderate (30-90%)

G-CSF

Not routine

Used in

Non-small-cell lung cancer

Products

PembrolizumabCarboplatinPaclitaxel / nab-paclitaxel

Source

KEYNOTE-407, NEJM 2018

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.